July 12, 2007 8:00am EDT
Download as PDF
MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK) today
announced that that the U.S. Department of Justice has granted early
termination of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976 in connection with the potential acquisition of
additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and
Chairman of Opko. Dr. Frost has requested clearance to purchase additional
shares of Opko Health common stock, which this action by the Justice
Department now makes feasible.
About Opko Health, Inc.
Miami-based Opko is a specialty healthcare company. Its lead
investigational drug, the pioneering gene silencing agent bevasiranib, has
entered a pivotal Phase 3 trial after successfully completing Phase 2 trials
for wet age-related macular degeneration and macular degeneration. Opko is
developing a pre-clinical pipeline of novel agents for ophthalmic diseases,
and it also intends to market diagnostic systems that complement its
therapeutic products. The company recently announced it has entered into an
agreement to acquire Ophthalmic Technologies, Inc. (OTI), a provider of
innovative patient imaging systems to eye care professionals worldwide.
Corporate: GendeLLindheim BioCom Partners
Steven D. Rubin Barbara Lindheim
305 575 6015 212 918-4650
SOURCE Opko Health Inc.
Released July 12, 2007
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page